Quarterly report pursuant to Section 13 or 15(d)

REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)

v3.23.1
REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)
3 Months Ended
Mar. 31, 2023
REVENUES FROM CONTRACTS WITH CUSTOMERS  
Schedule of disaggregation of net revenues

​

​

​

​

​

​

​

​

​

​

Three-Month Period Ended March 31, 

($ in thousands)

    

2023

    

2022

Qbrexza®

​

$

4,094

​

$

7,376

Accutane®

​

 

4,648

​

 

4,907

Amzeeq®

​

​

1,193

​

​

3,466

Targadox®

​

​

793

​

​

2,634

Ximino®

​

​

612

​

​

967

Exelderm®

​

 

511

​

 

704

Zilxi®

​

​

314

​

​

741

Other branded revenue

​

 

—

​

 

1

Total product revenues

​

$

12,165

​

$

20,796

​

Schedule of other revenue

​

​

​

​

​

​

​

​

​

    

Three-Month Period Ended March 31,

($ in thousands)

    

2023

    

2022

Other revenue

 

$

48

 

$

2,500

Total other revenue

​

$

48

​

$

2,500

​